HanchorBio today announced that its proprietary HCB101, a SIRPa/CD47 fusion protein candidate, has been officially granted a US patent (Patent No.

(Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced efficacy and safety results of the positive pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for ...

Developing new topical drugs or cosmetics requires a long, expensive research and marketing process, with each launch ...

TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ — HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US ...

Witness the behind-the-scenes delivery of the impressive life-sized Lamborghini Sian model built mostly from LEGO bricks, now ...

When I first realized the scale of the challenge posed by neurodegenerative diseases, such as Alzheimer's, Parkinson's ...

PLPC-DB , a non-cellular immunobiological module validated under FDA-aligned documentation for adaptive biotechnology.

Yang, Y. (2025) Research Progress of Nano ZnO and Its Composites in the Field of Antibacterial Technology. Journal of Biomaterials and Nanobiotechnology, 16, 31-38. doi: 10.4236/jbnb.2025.163003 .

Next month’s election in Northern Colorado and the Boulder Valley will be brimming with citizen-initiated ballot issues that ...

Researchers identify FGFR4, FLT1, and WNT5A as key biomarkers and suggest dovitinib and nintedanib as new targeted therapies ...

Explore the impact of lysosomal lipid recycling in a rare multi-organ disorder linked to the SPNS1 gene mutations.

Sana Biotechnology, Inc. is working on a gene therapy to cure Type 1 diabetes. Click here to find out why SANA stock is a ...